

ScinoPharm to manufacture Supernus epilepsy drug

September 10, 2013 | News | By BioSpectrum Bureau



Singapore: Taiwan-based ScinoPharm will provide commercial manufacturing of topiramate active pharmaceutical ingredient (API) for Trokendi XR, which was developed and recently launched by Supernus Pharmaceuticals in the US market. Supernus received approval to market Trokendi XR by the US FDA in August 2013.

Trokendi XR is a novel once-daily extended release formulation of topiramate for the treatment of epilepsy.

Unlike other antiepileptic drugs (AED) that require multiple doses, Trokendi XR is a novel once-daily extended-release formulation designed to improve compliance and reduce blood level fluctuations that can be associated with side effects and breakthrough seizures.

According to the data from the US Centers for Disease Control (CDC) and Prevention, there are approximately two million epilepsy sufferers in the US. The new drug is expected to attract market attention after being offered to the public.

"ScinoPharm is proud of our longstanding partnership with Supernus. We are committed to providing Supernus and our other customers with high quality APIs, combining with a flexible, reliable, and competitive approach," remarked Dr Jo Shen, president and CEO, ScinoPharm.